Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S‐1 chemotherapy after gastrectomy: A multicenter, open‐label, single‐arm, prospective phase II study (OGSG1108)
暂无分享,去创建一个
H. Imamura | D. Sakai | T. Satoh | T. Tsujinaka | H. Furukawa | Y. Kurokawa | T. Shimokawa | J. Kawada | K. Fujitani | Y. Matsubara | Y. Kimura | H. Kawakami | J. Matsuyama | K. Nishikawa | J. Fukui | S. Endo | T. Kawase
[1] D. Cunningham,et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Chad A. LaGrange,et al. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[3] H. Imamura,et al. Long‐term effects of an oral elemental nutritional supplement on post‐gastrectomy body weight loss in gastric cancer patients (KSES002) , 2019, Annals of gastroenterological surgery.
[4] G. Lyman,et al. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer , 2019, Supportive Care in Cancer.
[5] H. Kuwano,et al. A prospective pilot study of an elemental nutritional supplement for prevention of oral mucositis during S-1 adjuvant chemotherapy for gastric cancer. , 2019, Surgical oncology.
[6] Gang Zhao,et al. Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. , 2019, JAMA.
[7] Y. Kodera,et al. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Kazuhiro Yoshida,et al. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy , 2018, Annals of Surgical Oncology.
[9] R. Wenham,et al. Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. , 2018, Gynecologic oncology.
[10] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[11] T. Yoshikawa,et al. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer , 2017, International Journal of Clinical Oncology.
[12] H. Imamura,et al. Effects of an Oral Elemental Nutritional Supplement on Post-gastrectomy Body Weight Loss in Gastric Cancer Patients: A Randomized Controlled Clinical Trial , 2016, Annals of Surgical Oncology.
[13] E. Oki,et al. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Kazuhiro Yoshida,et al. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study , 2016, Gastric Cancer.
[15] D. Shin,et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[16] A. Ejaz,et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. , 2014, Journal of the American College of Surgeons.
[17] F. Qi,et al. Adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis , 2014, Scandinavian journal of gastroenterology.
[18] F. Ciardiello,et al. Treatment of gastric cancer. , 2014, World journal of gastroenterology.
[19] T. Yoshikawa,et al. Body Weight Loss After Surgery is an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer , 2013, Annals of Surgical Oncology.
[20] D. Park,et al. Safety, compliance, and predictive parameters for dosage modification in adjuvant S‐1 chemotherapy for gastric cancer , 2013, Cancer science.
[21] Y. Bang,et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.
[22] Y. Ohashi,et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] H. Wilke,et al. Treatment strategies in gastric cancer. , 2011, Deutsches Arzteblatt international.
[24] Yasuo Ohashi,et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.
[25] G. Bonadonna,et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.
[26] Kazuhiro Yoshida,et al. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy , 2015, Gastric Cancer.
[27] Hodgkin Lymphoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .
[28] Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition , 2011, Gastric Cancer.
[29] Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3) , 2011, Gastric Cancer.
[30] 胃癌研究会. Japanese classification of gastric carcinoma , 1995 .